ALNYLAM PHARMACEUTICALS, INC.
Recent Filings
All 1,000 filings →| Form | Description | Date |
|---|---|---|
| SCHEDULE 13G/A | — | Mar 26, 2026 |
| 4 | PRIMARY DOCUMENT | Mar 6, 2026 |
| 4 | PRIMARY DOCUMENT | Mar 6, 2026 |
| 4 | PRIMARY DOCUMENT | Mar 6, 2026 |
| 4 | PRIMARY DOCUMENT | Mar 6, 2026 |
| 4 | PRIMARY DOCUMENT | Mar 6, 2026 |
| 144 | — | Mar 5, 2026 |
| 144 | — | Mar 5, 2026 |
| 4 | PRIMARY DOCUMENT | Mar 4, 2026 |
| 4 | PRIMARY DOCUMENT | Mar 4, 2026 |
Insider Transactions
View all →| Insider | Title | Type | Shares | Owns After | Date |
|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sale | 295 @ $463.08 | 21,264 | Nov 17, 2025 |
| Greenstreet Yvonne | Chief Executive Officer | Sale | 1,069 @ $453.52 | 74,229 | Nov 12, 2025 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | Award / Grant | 4,644 | 57,873 | Oct 2, 2025 |
| Greenstreet Yvonne | Chief Executive Officer | Sale | 1,010 @ $451.86 | 69,854 | Oct 2, 2025 |
| Tanguler Tolga | EVP, Chief Commercial Officer | Sale | 1 @ $457.64 | 27,438 | Oct 2, 2025 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sale | 122 @ $457.43 | 25,234 | Oct 2, 2025 |
| Garg Pushkal | EVP Chief R&D | Sale | 215 @ $454.37 | 20,221 | Oct 2, 2025 |
| SUPRAN BRYAN | EVP, CLO and Secretary | Award / Grant | 13,026 | 13,026 | Oct 1, 2025 |
| Reitan Colleen F | — | Sale | 951 @ $474.85 | 5,791 | Sep 9, 2025 |
| Tanguler Tolga | EVP, Chief Commercial Officer | Sale | 144 @ $452.49 | 25,992 | Aug 29, 2025 |